Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
NCT06812429Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapagliflozin in inflammation, sponsored by Washington University School of Medicine. Primary endpoint: Change from baseline in the markers of Inflammation at 3 days. Started May 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT06812429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812429.